A Bi-Functional Targeted P28-NRC Chimeric Protein with Enhanced Cytotoxic Effects on Breast Cancer Cell Lines

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Chimeric proteins represent an emerging strategy for targeted cancer therapy.
• The p28 peptide selectively enters and activates apoptosis in breast cancer cells.
• The NRC antimicrobial peptide exhibits cytotoxicity against various breast cancer cell lines, including drug-resistant ones.

Purpose of the Study:

• To design and evaluate a chimeric protein combining p28 and NRC peptides.
• To determine the targeted effects and enhance the cytotoxic activity against breast cancer cells.
• To elucidate the mechanism of cell death induced by the chimeric protein.

Main Methods:

• Design and synthesis of a chimeric protein comprising p28 and NRC peptides.
• Cytotoxicity assays on MDA-MB-231 and MCF7 breast cancer cell lines.
• Flow cytometry analysis to investigate the mechanism of cell death (apoptosis).

Main Results:

• The chimeric protein exhibited dose-dependent cytotoxicity against MDA-MB-231 and MCF7 cells after 48 hours.
• Cytotoxic effects of the chimeric protein were significantly higher than p28 peptide alone, indicating additive or enhanced activity.
• Flow cytometry confirmed that cell death was mediated via apoptosis, involving mitochondrial caspase-dependent and -independent pathways in MCF7 cells.

Conclusions:

• The designed chimeric protein demonstrates enhanced anti-cancer effects on breast cancer cell lines.
• The study suggests the chimeric protein is a potential anti-cancer agent.
• Further in-vitro and in-vivo preclinical studies are warranted to evaluate its therapeutic potential.